Adragos Turns Sanofi's Castoffs Into a European Crown Jewel

Adragos Pharma acquires Sanofi's Maisons-Alfort facility, cementing its place at the heart of Europe's sterile injectables market

4 May 2026

Adragos Pharma, a Munich-based contract drug manufacturer, has acquired Sanofi's sterile fill-finish facility in Maisons-Alfort, outside Paris, in a deal completed in April 2026. The acquisition adds large-scale production of pre-filled syringes and injectable vials to Adragos' network, along with manufacturing approvals from health authorities in France, China, South Korea and Brazil.

All staff at the site will be retained.

The Maisons-Alfort deal is Adragos' second purchase from Sanofi. In 2023, the company acquired a Japanese manufacturing site from the French drugmaker under a five-year supply agreement. The repeat transaction points to a structured and ongoing relationship between the two companies, based on regulatory continuity rather than a straightforward asset sale.

Adragos is backed by FSN Capital, a Nordic private equity firm, which has supported its strategy of acquiring high-quality European sterile manufacturing assets. The global market for sterile injectable contract manufacturing is projected to reach $7.36bn in 2026, growing at roughly 11 per cent per year, as demand for biologics and biosimilars rises.

Revised EU good manufacturing practice rules, known as Annex 1, came into mandatory effect in 2023, raising the technical requirements for aseptic drug production across the continent. Contract manufacturers able to meet those standards consistently, and across multiple regulatory frameworks, are gaining a competitive edge as large pharmaceutical companies look for specialist production partners.

With facilities now in Switzerland, Livron and Maisons-Alfort in France, Adragos operates a multi-site European network for sterile injectables. Whether the company pursues further acquisitions to consolidate that position remains to be seen.